AEON Biopharma, Inc. (AEON)vsAlnylam Pharmaceuticals Inc (ALNY)
AEON
AEON Biopharma, Inc.
$0.71
-2.12%
HEALTHCARE · Cap: $18.99M
ALNY
Alnylam Pharmaceuticals Inc
$301.67
-0.19%
HEALTHCARE · Cap: $39.26B
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 12.6% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
AEON
Avoid17
out of 100
Grade: F
ALNY
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AEON.
Margin of Safety
+86.3%
Fair Value
$2354.68
Current Price
$301.67
$2053.01 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AEON
The strongest argument for AEON centers on Debt/Equity.
Bull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bear Case : AEON
The primary concerns for AEON are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 74.1x leaves little room for execution misses.
Key Dynamics to Monitor
AEON profiles as a value stock while ALNY is a growth play — different risk/reward profiles.
AEON carries more volatility with a beta of 0.61 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 17/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AEON Biopharma, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. The company is headquartered in Newport Beach, California.
Visit Website →Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?